Azịza ngwa ngwa
You are a peptide program lead deciding what to do with your program this quarter, and the governance picture in front of you is genuinely mixed. The Senate HE…
Kedu ihe gbanwere na FDA na 2026, na ihe ka bụ naanị nhọpụta?
Onye na-eweta ozi Peptide Ụlọ ọrụ Peptides Co., Ltd Ntị nhọpụta anaghị n'onwe ya agbanwe nnabata peptide, Ngwakọta ma ọ bụ mma chọrọ. Nyochaa omume enyere iche: Julaị 2026 ntụzigharị peptide na nyocha amụma na-echere October nwere ọkwa na oke nke ha. Mkparịta ụka onye ndu ekwesịghị dochie nyocha ahụ akọwapụtara nke ọma.
Ajụjụ kọmitii ndụmọdụ bụ ebe kọmitii ndụmọdụ FDA peptide na-etinye aka na mgbanwe ndu. Ndị omebe iwu kwadoro Overton itinye aka n'ịkwalite kọmitii ndụmọdụ FDA ike ma chọọ mmesi obi ike na kọmitii ahụ ga-ejigide ọrụ ha., megide ndabere nke roughly 50 kọmitii ndụmọdụ sayensị na nka na ụzụ na kọmitii ndị na-agbakọ obere oge (na-akọ akụkọ n'ịnụ nkwenye, C&N'ime, 2026). Iche iche, mkpesa na-akọwa ngbanwe nke akwụkwọ ndekọta PCAC n'ihu nzukọ Julaị, ya na ndị otu nwere njikọ peptide-ụlọ ọrụ agbakwunyere (Akwụkwọ ndekọ aha kwuru mgbanwe tupu votu ahụ, Pharmaforum, 2026). Akaụntụ ahụ bụ otu isi mmalite na-enyeghị ọnụ ọgụgụ ndị otu, ya mere na-emeso ya dị ka a kọrọ kama guzosie ike.
|
Eziokwu usoro akwadoro |
Ka oghe |
|---|---|
|
Emere nhọpụta nhọpụta 24 Septemba 2026 |
Enweghị votu kọmitii; ọ dịghị ala votu mara ọkwa |
|
Onye na-arụ ọrụ kọmishọna nọ n'ọnọdụ, ọ bụghị Sineti-kwetara |
Ma, na mgbe, Kọmishọna a kwadoro na-ewe ọrụ |
|
PCAC zutere 23–24 Julaị 2026 ma mee ntuli aka |
Ihe FDA na-eme na ndụmọdụ |
|
Amụma nnweta nwa oge gara na OMB 14 October 2026 |
Ma ọ na-ekwu, kedu udi, ma ọ bụ ewepụrụ |
Kedu ihe panel ndụmọdụ peptide mere votu na, na gịnị ka votu ahụ na-eme n'ụzọ iwu kwadoro?
Ọnwa Julaị 2026 votu kwadoro, ọ dịghịkwa ihe ọzọ. Nkọwa FDA n'onwe ya banyere otu kọmitii ndụmọdụ na-arụ ọrụ na-ekwu na ndụmọdụ bụ "naanị nke ahụ, ndụmọdụ, ma ejikọtala ụlọ ọrụ ahụ na mkpebi ọ bụla," na mkpebi ikpeazụ nke iwu na-adabere na ụlọ ọrụ ahụ (Nkọwa nke FDA nke otu kọmitii ndụmọdụ si arụ ọrụ, ugbu a 2026). Asụsụ akwụkwọ ikike nke kọmitii na Federal Register na-ahazi ọrụ ya dị ka inye ndụmọdụ kwesịrị ekwesị nye Kọmishọna maka ịgbakọ n'okpuru ngalaba 503A na 503B. (Asụsụ akwụkwọ ikike nke kọmitii na Federal Register, 2015).
<klas ọgụgụ ="blọọgụ-akara ngosi" ụdị ="oke-obosara:640px;oke:1.5rem akpaaka;font-nha:12px;ahịrị-ịdị elu:1.3;agba:eketa"> <svg viewBox="0 0 560 380" ụdị ="oke-obosara: 100%; elu: akpaaka; font-ezinụlọ: 'Inter', usoro-ui, sans-serif; agba: #1e293b; --chaatị-mechiri emechi: #64748b;" ọrụ ="img" aria-labeledby="pcc-peptide-votes-July-2026- aha pac-peptide-votes-july-2026-desc"> <ịke> /* Onye nrụpụta na-etinye eserese ahụ n'ime iframe nke ihe ndabere ya dị oji, na iframe bụ ọdịdị dị iche na chaatị ahụ, ya mere eriri igbe akwụkwọ ozi gosipụtara dị ka okpokolo agba gbara ya gburugburu (prod 09-22). Akwụkwọ dị n'ime iframe pụtara ìhè na ndabara; esere ya ebe a na-ekpuchi ndabere elementrị, na mgbe e debere chaatị ahụ kama nke a dabara na ihe ọ bụla. Debe brackets n'akuku na ngọngọ a: A na-atụgharị akụkụ ụdị n'ime SVG dị ka ọdịnaya nke mba ọzọ, ya mere otu nkwado kpafuru akpafu na-atụfu iwu niile dị na ya. */ html, ahu { ndabere: #fffff; oke: 0; } @mgbasa ozi (na-ahọrọ-ebelata-mmegharị: belata) { * { animation: onweghi !mkpa; mgbanwe: onweghi !mkpa; } } </ịke> <ziri ezi x="0" y="0" obosara ="560" elu ="380" rx="8" juru ="#fffff" /> <aha id="pac-peptide-vote-July-2026- aha">PCAC peptide votes, Julaị 2026</aha> <desc id ="pac-peptide-votes-July-2026-desc">PCAC peptide votes, Julaị, dị ka e si kpaa nkata site n'isi iyi e zoro aka na ya. PCAC peptide votes, Julaị 2026. data mmanya agbakọtara: BPC-157: Ee 8, Mba 6, Zere 1; KPV: Ee 8, Mba 6, Zere 1; TB-500: Ee 8, Mba 6, Zere 1; c-OKWU: Ee 7, Mba 5, Zere 2; egela ntị: Ee 8, Mba 5, Zere 1; Epitalon: Ee 7, Mba 4, Zere 1; Emideltide/DSIP: Ee 6, Mba 7, Akwụsị 1.Isi iyi: McDermott ga- & Emery, PCAC mkpegharị 2026-07-28.</desc> <ederede x ="280.0" y="29" ederede-arịlịka ="etiti" font-size ="18" font-arọ="800" juru ="Agba ugbu a">PCAC peptide votes, Julaị 2026</ederede> <ahịrị x1="72" y1="277.0" x2="492" y2="277.0" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ahịrị x1="72" y1="230.8" x2="492" y2="230.8" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ahịrị x1="72" y1="184.5" x2="492" y2="184.5" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ahịrị x1="72" y1="138.2" x2="492" y2="138.2" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ahịrị x1="72" y1="92.0" x2="492" y2="92.0" ọrịa strok ="Agba ugbu a" opacity="0.08" /> <ederede x ="66" y="281.0" ederede-arịlịka ="ngwucha" font-size ="10" juru ="Agba ugbu a" opacity="0.7">0</ederede> <ederede x ="66" y="234.8" ederede-arịlịka ="ngwucha" font-size ="10" juru ="Agba ugbu a" opacity="0.7">2.5</ederede> <ederede x ="66" y="188.5" ederede-arịlịka ="ngwucha" font-size ="10" juru ="Agba ugbu a" opacity="0.7">5</ederede> <ederede x ="66" y="142.2" ederede-arịlịka ="ngwucha" font-size ="10" juru ="Agba ugbu a" opacity="0.7">7.5</ederede> <ederede x ="66" y="96.0" ederede-arịlịka ="ngwucha" font-size ="10" juru ="Agba ugbu a" opacity="0.7">10</ederede> <ziri ezi x="72.0" y="62" obosara ="10" elu ="10" juru ="#f97316" /> <ederede x ="87.0" y="71" font-size ="11" juru ="Agba ugbu a">Ee</ederede> <ziri ezi x="127.6" y="62" obosara ="10" elu ="10" juru ="#38bdf8" /> <ederede x ="142.6" y="71" font-size ="11" juru ="Agba ugbu a">Mba</ederede> <ziri ezi x="177.0" y="62" obosara ="10" elu ="10" juru ="#nke 78bfa" /> <ederede x ="192.0" y="71" font-size ="11" juru ="Agba ugbu a">Zere</ederede> <ziri ezi x="79.0" y="129.0" obosara ="13.3" elu ="148.0" juru ="#f97316" /> <ederede x ="85.7" y="125.0" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">8</ederede> <ziri ezi x="94.3" y="166.0" obosara ="13.3" elu ="111.0" juru ="#38bdf8" /> <ederede x ="101.0" y="162.0" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">6</ederede> <ziri ezi x="109.7" y="258.5" obosara ="13.3" elu ="18.5" juru ="#nke 78bfa" /> <ederede x ="116.3" y="254.5" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">1</ederede> <ederede x ="102.0" y="295.0" ederede-arịlịka ="etiti" font-size ="10" juru ="Agba ugbu a" opacity="0.8"><otu x ="102.0" dy="0">BPC-157</tsp></ederede> <ziri ezi x="139.0" y="129.0" obosara ="13.3" elu ="148.0" juru ="#f97316" /> <ederede x ="145.7" y="125.0" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">8</ederede> <ziri ezi x="154.3" y="166.0" obosara ="13.3" elu ="111.0" juru ="#38bdf8" /> <ederede x ="161.0" y="162.0" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">6</ederede> <ziri ezi x="169.7" y="258.5" obosara ="13.3" elu ="18.5" juru ="#nke 78bfa" /> <ederede x ="176.3" y="254.5" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">1</ederede> <ederede x ="162.0" y="295.0" ederede-arịlịka ="etiti" font-size ="10" juru ="Agba ugbu a" opacity="0.8"><otu x ="162.0" dy="0">KPV</tsp></ederede> <ziri ezi x="199.0" y="129.0" obosara ="13.3" elu ="148.0" juru ="#f97316" /> <ederede x ="205.7" y="125.0" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">8</ederede> <ziri ezi x="214.3" y="166.0" obosara ="13.3" elu ="111.0" juru ="#38bdf8" /> <ederede x ="221.0" y="162.0" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">6</ederede> <ziri ezi x="229.7" y="258.5" obosara ="13.3" elu ="18.5" juru ="#nke 78bfa" /> <ederede x ="236.3" y="254.5" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">1</ederede> <ederede x ="222.0" y="295.0" ederede-arịlịka ="etiti" font-size ="10" juru ="Agba ugbu a" opacity="0.8"><otu x ="222.0" dy="0">TB-500</tsp></ederede> <ziri ezi x="259.0" y="147.5" obosara ="13.3" elu ="129.5" juru ="#f97316" /> <ederede x ="265.7" y="143.5" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">7</ederede> <ziri ezi x="274.3" y="184.5" obosara ="13.3" elu ="92.5" juru ="#38bdf8" /> <ederede x ="281.0" y="180.5" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">5</ederede> <ziri ezi x="289.7" y="240.0" obosara ="13.3" elu ="37.0" juru ="#nke 78bfa" /> <ederede x ="296.3" y="236.0" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">2</ederede> <ederede x ="282.0" y="295.0" ederede-arịlịka ="etiti" font-size ="10" juru ="Agba ugbu a" opacity="0.8"><otu x ="282.0" dy="0">c-OKWU</tsp></ederede> <ziri ezi x="319.0" y="129.0" obosara ="13.3" elu ="148.0" juru ="#f97316" /> <ederede x ="325.7" y="125.0" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">8</ederede> <ziri ezi x="334.3" y="184.5" obosara ="13.3" elu ="92.5" juru ="#38bdf8" /> <ederede x ="341.0" y="180.5" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">5</ederede> <ziri ezi x="349.7" y="258.5" obosara ="13.3" elu ="18.5" juru ="#nke 78bfa" /> <ederede x ="356.3" y="254.5" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">1</ederede> <ederede x ="342.0" y="295.0" ederede-arịlịka ="etiti" font-size ="10" juru ="Agba ugbu a" opacity="0.8"><otu x ="342.0" dy="0">egela ntị</tsp></ederede> <ziri ezi x="379.0" y="147.5" obosara ="13.3" elu ="129.5" juru ="#f97316" /> <ederede x ="385.7" y="143.5" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">7</ederede> <ziri ezi x="394.3" y="203.0" obosara ="13.3" elu ="74.0" juru ="#38bdf8" /> <ederede x ="401.0" y="199.0" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">4</ederede> <ziri ezi x="409.7" y="258.5" obosara ="13.3" elu ="18.5" juru ="#nke 78bfa" /> <ederede x ="416.3" y="254.5" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">1</ederede> <ederede x ="402.0" y="295.0" ederede-arịlịka ="etiti" font-size ="10" juru ="Agba ugbu a" opacity="0.8"><otu x ="402.0" dy="0">Epitalon</tsp></ederede> <ziri ezi x="439.0" y="166.0" obosara ="13.3" elu ="111.0" juru ="#f97316" /> <ederede x ="445.7" y="162.0" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">6</ederede> <ziri ezi x="454.3" y="147.5" obosara ="13.3" elu ="129.5" juru ="#38bdf8" /> <ederede x ="461.0" y="143.5" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">7</ederede> <ziri ezi x="469.7" y="258.5" obosara ="13.3" elu ="18.5" juru ="#nke 78bfa" /> <ederede x ="476.3" y="254.5" ederede-arịlịka ="etiti" font-size ="9" juru ="Agba ugbu a">1</ederede> <ederede x ="462.0" y="295.0" ederede-arịlịka ="etiti" font-size ="10" juru ="Agba ugbu a" opacity="0.8"><otu x ="462.0" dy="0">Emideltide/DSIP</tsp></ederede> <ederede x ="280.0" y="366" ederede-arịlịka ="etiti" font-size ="10" juru ="anyi(--chaatị-mechiri emechi, Agba ugbu a)">Isi mmalite: McDermott ga- & Emery, PCAC nchịkọta (2026-07-28)</ederede> </svg> </ọgụgụ>
Ndekọ usoro ahụ ziri ezi. Eprel 2026 Akwụkwọ ndekọ aha Federal na-emeghe docket setịpụrụ nzukọ maka 23 na 24 Julaị 2026, docket FDA-2025-N-6895, na okwu mechiri emechi 22 Julaị 2026, na nkwupụta natara 9 July nyere kọmitii (Eprel 2026 Akwụkwọ ndekọ aha Federal na-emepe docket, 91 FR 20465). Ngụpụta nke ntuli aka siri ike na-akọ ọkwa dị n'okpuru; ọnweghị nkeji ọchịchị a chọtara, ya mere a na-akpọ ha dị ka a kọrọ na nzuko ọha (ngụpụta nke votu ndị ahụ siri ike, McDermott ga- & Emery, 2026).
|
Ihe |
Ee |
Mba |
Zere |
Nsonaazụ |
|---|---|---|---|---|
|
BPC-157 |
8 |
6 |
1 |
Akwadoro |
|
KPV |
8 |
6 |
1 |
Akwadoro |
|
TB- Peptides ozugbo 500 |
8 |
6 |
1 |
Akwadoro |
|
c-OKWU |
7 |
5 |
2 |
Akwadoro |
|
egela ntị |
8 |
5 |
1 |
Akwadoro |
|
Epitalon |
7 |
4 |
1 |
Akwadoro |
|
Emideltide (DSIP) |
1 |
A naghị atụ aro ya |
Nkewa 8-6-1 bụ nsonaazụ modal, na DSIP bụ naanị ihe kọmitii ahụ kwadoro megide. Ntuli aka dị mma etinyeghị ihe ọ bụla na ndepụta nnukwu 503A ma enyeghị ikike ịmekọ ihe. Nkọwa FDA nke ụdị nwa oge ya doro anya na mwepụ na ngalaba 2 naanị na-ebuli ọnọdụ anaghị agbakọta ọnụ; ọ bụghị ndepụta, na udi 1 bụ ọnọdụ enweghị mmanye karịa nkwado (Nkọwa FDA nke ụdị oge ya, ugbu a 2026).
Kedu ka a ga-esi nwetaghachi peptide n'ezie, na ogologo oge ka nke ahụ na-ewe?
Enweghị oge ngwụcha nke iwu, na ụkpụrụ na-aga n'ihu n'ime afọ, ọ bụghị ọnwa. Dị ka nke etiti October 2026 ọnweghị iwu a tụrụ aro ma ọ bụ nke ikpeazụ dị; FDA ga-ekpebi ma ọ ga-anabata ndụmọdụ ndị a, bipụta iwu atụpụtara, na-aza ajụjụ, wepụtazie iwu ikpeazụ, na ihe kacha nso bụ a 2016 tụrụ aro iwu na 10 nnukwu ihe emechaala na 2019 (Nlebanya ọkwa mbubreyo-October, Holland & Knight, 2026).
Nke 2019 iwu a tụrụ aro na-egosi ọdịdị nke nzọụkwụ ahụ. Ọ tụrụ aro idowe 5 bekee na ndepụta na ọ bụghị idobe 26 ndị ọzọ, tọọ okwu ruru 4 Disemba 2019, ma tụọ aro ka iwu ikpeazụ ọ bụla malite 30 ụbọchị mgbe e bipụtara ya (nke 2019 iwu tụrụ aro, 84 FR 46688). Nke January 2025 ọkwa amụma nwa oge na-agbakwunye ụkpụrụ njide: dị udi 1 ihe na-anọ n'ime iwu ruo mgbe FDA kwupụtara iwu ikpeazụ na-ekpebi ma a ga-etinye ha na ndepụta nnukwu 503A. (nke January 2025 ọkwa amụma nwa oge, 2025).
Ịdọ aka ná ntị: Ọ nweghị oge njedebe nke iwu na-achịkwa usoro a. Ndepụta 503A na 503B na-agbakwa n'ule iwu dị iche iche, ya mere ọganihu n'otu n'otu ekwughị ihe ọ bụla gbasara nke ọzọ.
Ụzọ 503B na-egosi ọdịiche ahụ. Nkwupụta FDA 503B na GLP-1 peptides tụrụ aro ka ọ ghara ịgụnye semaglutide., Tirzepatide na liraglutide, chọrọ dịkarịa ala 60 ụbọchị maka ikwu okwu, ma tinye nyocha-mkpa ụlọọgwụ nke na-ewepu ụkọ, mma na ọnụ ahịa (Ntuziaka FDA 503B na GLP-1 peptides, 91 FR 23431). Usoro nrịbama ndepụta nnukwu 503B bụ ọkwa ikwu okwu na-esote ọkwa ọkwa, na ụkọ ọnọdụ na-arụ ọrụ dị ka ụzọ dị iche iche karịa arụmụka mkpa ụlọ ọgwụ (503B nnukwu ndepụta ọkwa, 2026).
Usoro ise, ka ewere, onye ọ bụla na-enweghị nkwa nzọụkwụ ọzọ: Onye na-emepụta Peptide
-
PCAC votu (naanị ndụmọdụ)
-
Mkpebi FDA ma ị ga-anabata nkwanye
-
Ebipụtara iwu atụpụtara
-
Oge nkọwa (90 ụbọchị n'ime 2019 ihe mbu; opekempe 60 ụbọchị na egwu 503B)
-
Iwu ikpeazụ, dị irè 30 ụbọchị mgbe e bipụtachara ya n'usoro ihe atụ ahụ
Kedu ihe data nyocha nke ịdịmma mkpebi pụtara maka peptide, ubi site na ubi?
Ngwungwu njirimara peptide bụ mma mkpebi mgbe ejikọtara ọnụọgụ ọ bụla na usoro akpọrọ, kọlụm akọwara na ogologo nchọta kwuru, na mgbe e guzobe njirimara orthogonally kama ịpụta site na ịdị ọcha. I Q2(R2), nakweere na Nzọụkwụ 4 na Nọvemba 2023, na-akọwapụta njirimara arụmọrụ otu usoro ga-egosipụtarịrị wee nyegharịa “agwa nkwado” dị ka “ụkpụrụ arụmọrụ” (I Q2(R2), nakweere na Nzọụkwụ 4 na Nọvemba 2023, I, 2023).
|
Q2(R2) njirimara arụmọrụ |
Nnwale peptide na-eme ya |
|---|---|
|
Nkọwapụta / nhọrọ |
njirimara Orthogonal: nkwenye oke n'akụkụ njide chromatographic |
|
Oke, gụnyere oke ala, DL na QL |
Linearity gafee oke ọrụ, na mmakwado oke adịghị ọcha |
|
izi ezi |
Iweghachi megide ụkpụrụ ntụaka nke ọdịnaya amaara |
|
Nkenkenke (repeatability, etiti, reproducibility) |
Tinyegharịa injections kwa ụbọchị, ogidi na ndị nyocha |
|
Ike |
Usoro nrụgide nke ụma: gradient, okpomọkụ, ogologo ife efe |
Otu ngwungwu kwesịrị iburu usoro njirimara, chromatogram na ọ bụghị naanị ọnụ ọgụgụ dị ọcha, nsonaazụ orthogonal, counterion na net-peptide ọdịnaya, mmiri ọdịnaya, endotoxin sitere na USP <85> LAL ebe ihe a na-agbanye ọgwụ, na ịmụ nwa site na USP <71>, nke dị iche na USP <61> ọnụ ọgụgụ microbial. Enweghị monograph USP amapụtara maka BPC-157, KPV, TB-500, c-OKWU, Epitalon, Semax ma ọ bụ emideltide, Ya mere, isiakwụkwọ USP na-etinye dị ka usoro nyocha karịa nkọwa kpọmkwem peptide.
Ntugharị igodo: Dị ọcha nke akọwara dị ka pasent ebe ikwu abụghị njirimara, ọdịnaya, nkwụsi ike ma ọ bụ nleba anya dabara n'onwe ya.
Ngwungwu ndị na-ebubata ihe na-agụ "RP-HPLC, kọlụm C18, mmiri / acetonitrile gradient, Nchọpụta UV na 220 nm, ịdị ọcha 99.2%” na chromatogram agbakwunyere na-enyocha ya. Ahịrị na-agụ “HPLC ịdị ọcha: 99%"bụghị, n'ihi na a pụghị imepụtagharị ya ma ọ bụ gbaa aka.
Kedu ka esi eme nyocha, nkwadebe jikọtara ọnụ na ọgwụ akwadoro dị iche na akaebe na akwụkwọ?
Ọgwụ akwadoro, nkwado nkwado iwu kwadoro na ihe nyocha dị iche na usoro iwu na ihe akaebe. Ngalaba 216.23(d) gbasara ihe ndị e depụtara na ndokwa ahụ; ọ naghị egosi na ọgwụ ọ bụla jikọtara ọnụ enweghị nchekwa ma ọ bụ ihe akaebe dị irè.
|
Ihe eji eme nyocha |
Ngwakọta 503A nkwadebe |
Ọgwụ peptide akwadoro |
|
|---|---|---|---|
|
Ọkwa nkwado |
Ọ dịghị |
Ọ dịghị; ndenye ọgwụ na-eduzi |
NDA ma ọ bụ BLA |
| Ihe akaebe nchekwa na arụmọrụ | Dabere na ajụjụ nyocha; enweghị nkwado ọgwụ pụtara | Ọ bụghị FDA premarket-akwadoro; ihe akaebe dị iche iche site na nkwadebe na ojiji | Atụlela maka egosi akwadoro yana ụzọ nkwado ọdabara |
|
Nkwenye nrụpụta |
Nnwale usoro naanị |
Nnukwu ihe ga-abụ nke iwu kwadoro |
Usoro kwadoro, akwadoro nkọwa |
|
Ịkpọ aha |
Nyocha-iji naanị |
Ịkpọ aha agwakọtara |
Ntinye aha akwadoro |
| Ọrụ post-ahịa | Dabere na ọrụ na ikike | Ọdabara gọọmentị etiti na steeti chọrọ; chọrọ dị iche site na ụzọ | Ọdabara nchekwa akụkọ na onyunyo |
Ịkpọ aha anaghị edozi ebumnobi. Otu August 2026 akwụkwọ ozi ịdọ aka ná ntị chọpụtara na nyocha-eji naanị na-abụghị maka mmadụ-eri nri emeghị ka ebumnobi na-abụghị ọgwụ eme ka ebe nrụọrụ weebụ na-ekwu gbakwunyere ire mmiri bacteriostatic dị ka ihe mgbaze na-emezigharị gosipụtara iji mmadụ eme ihe., ọ kpọkwara semaglutide, retatrutide, SS-31, PT-141 na Tesamorelin (otu August 2026 leta ịdọ aka ná ntị, FDA, Ref. 735127). Mwepụ na ngalaba 2 na-ebuli ọnọdụ adịghị-agbakọta naanị, na ntuli aka dị mma na-agbanwe ọ dịghị nke ọ bụla n'ime ogidi atọ dị n'elu.
Kedu akara kwesịrị ka elekere na-eduzi mmemme, na ihe mkpebi nke ọ bụla na-akpalite?
Mgbama ọ bụla n'okpuru maapụ maka otu mkpebi, yabụ na ị naghị ekpeghachi otu ajụjụ ahụ kwa ọnwa. Egwu nhọpụta bụ nke mbụ: votu kọmitii ma ọ bụ votu ala na Overton bụ ihe na-akpali gụgharịa ihe ụlọ ọrụ ahụ kwuru na-ebute ụzọ, ma ruo mgbe ahụ onye na-ahụ maka ọrụ kọmishọna na-anọgide na-abụ eziokwu (Kọmitii Enyemaka Sineti nke Septemba 2026 nhọpụta nhọpụta, 2026).
|
Signal |
Ihe ọ pụtara |
Mkpebi ọ na-akpalite |
|---|---|---|
|
Kọmitii Senate ma ọ bụ votu n'ala na nhọpụta |
Ajụjụ onye ndu na-edozi |
Ntụgharịghachi echiche usoro iwu na atụmatụ mmemme gị |
|
Mwepụta ma ọ bụ mwepu nke iwu ịnweta nwa oge nyefere OMB na 14 October 2026 |
ikike mmanye, ọ bụghị nkwado |
Debe ọkwa nkwenye pụọ na echiche mmemme ọ bụla |
| Mbipụta nke iwu 503A chọrọ | A akwụkwọ amụma nwere oge ikwu nke ya | Hazie ihe ndapụta site na ọkwa ahụ n'ezie; enweghị oge mmecha a na-ekwe nkwa |
|
Mkpebi ikpeazụ 503B na GLP-1 peptides |
Otu ndepụta na-akpali, nke ọzọ adịghị |
Ebufeela ọganihu 503B gaa na echiche 503A |
| Ọkwa ọkwa maka nzụkọ PCAC ọzọ | Ntụle ndụmọdụ ndụmọdụ agbakwunyere ma ọ bụrụ na ahaziri ya | Gụọ usoro na ụbọchị ndị e bipụtara tupu ị dabere na amụma |
Iwu nnweta nwa oge etinyere OMB na 14 October 2026 enyebeghị ya, na ụzọ nwere ike dị nso bụ ikike mmanye, nke na-akwado enweghị ngwaahịa yana enwere ike iwepụ ya na-enweghị usoro iwu; A na-atụ anya nzụkọ PCAC nke abụọ tupu ọgwụgwụ-February 2027 maka GHK-Cu, LL-37, Dihexa, Melanotan II na PEG-MGF (Nlebanya ọkwa mbubreyo-October, Holland & Knight, 2026).
Usoro mkpebi nke na-ejide n'agbanyeghị otú nyocha ahụ si edozi bụ nke a: were data njirimara dị ka naanị mgbanwe ị na-achịkwa, ma wuo ngwugwu nza na ọkwa usoro ugbu a. Ọ bụrụ na ị ga-achọ benchmark akwụkwọ ndị na-ebubata gị ugbu a megide ọkọlọtọ ahụ, ịrịọ ngwungwu data akọwapụtara nke ọma na ịgafe ya na ndepụta ubi dị n'elu na ọkachamara teknụzụ bụ otu ụzọ isi mee ya..
Ajụjụ a na-ajụkarị
Ọ na-eme na July 2026 votu kọmitii ndụmọdụ na-eme ka peptides ndị a bụrụ nke iwu kwadoro?
Mba. FDA na-ekwu na ndụmọdụ kọmitii ndụmọdụ anaghị ejikọta ụlọ ọrụ ahụ, na ntuli aka dị mma etinyeghị ihe ọ bụla na ndepụta nnukwu 503A (Nkọwa nke FDA nke otu kọmitii ndụmọdụ si arụ ọrụ, ugbu a 2026). Mwepụ na ngalaba 2 na-ebuli ọnọdụ adịghị-agbakọta naanị.
Ogologo oge ole ka a ga-edepụta peptide n'ezie?
Onweghi oge ngwụcha nke iwu dị. Ihe mbụ kacha nso bụ a 2016 iwu a tụrụ aro mechaa na 2019, na nke 2019 Iwu a tụrụ aro n'onwe ya buru oge ikwu okwu na-emechi December 4, 2019 na ụbọchị arụrụ arụ arụpụtara nke edobere na ngalaba VI (nke 2019 iwu tụrụ aro, 84 FR 46688).
Bụ akwụkwọ nyocha dị ka nkwenye?
Mba. Asambodo nyocha bụ nseta ihuenyo nke otu nza megide ụzọ akọwapụtara, na ọ dịghị anọchi anya ihu ọma, ikike, nchekwa ma ọ bụ arụmọrụ, ma ọ bụ ikike maka mmadụ ma ọ bụ anụmanụ. Rịọ maka usoro na chromatogram n'azụ ọnụ ọgụgụ ọ bụla.
Ịkpọ aha naanị nyocha-iji na-echebe onye na-ebubata ya?
Ọ bụghị n'onwe ya. Otu August 2026 akwụkwọ ozi ịdọ aka ná ntị chọpụtara na nyocha-eji naanị akara ngosi ewepụtaghị ebumnuche ọgwụ ebe nkwupụta weebụsaịtị na ire mmiri bacteriostatic gosipụtara ebumnuche mmadụ. (otu August 2026 leta ịdọ aka ná ntị, FDA, Ref. 735127).
Mmechi
Ihe ị nwere ike ime bụ data. Wulite ngwungwu nza na ọkwa usoro, na-ekwusi ike na chromatogram na nsonaazụ orthogonal, ma jidekwa ọdịiche dị n'etiti ịdị ọcha na njirimara nke ọma nke na isiokwu dị mma enweghị ike ime ka ọ dị nro. Mgbe ahụ lelee akara ngosi ise dị n'elu ka onye ọ bụla megharịa mkpebi kama inwe mmetụta.
Nzọụkwụ ọzọ bụ obere na ozugbo: Were otu ngwugwu nza ugbu a wee lelee ya megide ndepụta ubi na ngalaba njirimara. Ihe ọ bụla nyocha na-eme ọzọ, ngwugwu ahụ ka ga-abụ akụkụ nke mmemme gị ị nwere ike ịgbachitere.
Banyere onye nkwusa. MOL Mgbanwe bụ nyocha na nzukọ mmepe peptide na-enye nhazi usoro omenala, njikọ na ọrụ mgbanwe, na mmepụta nke peptides maka nyocha ụlọ nyocha na ngwa azụmahịa. Ọ nwere mmasị azụmahịa na ọkọnọ peptide, ya mere tulee echiche ya nke ọma. Ntuziaka dị n'elu anaghị adabere na ngwaahịa ya.
